Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 244

1.

Drug development for neglected diseases - the trouble with FDA review vouchers.

Kesselheim AS.

N Engl J Med. 2008 Nov 6;359(19):1981-3. doi: 10.1056/NEJMp0806684. No abstract available.

PMID:
18987367
[PubMed - indexed for MEDLINE]
Free Article
2.

FDA review vouchers.

Moe J, Grabowski H, Ridley D.

N Engl J Med. 2009 Feb 19;360(8):837; author reply 837-8. doi: 10.1056/NEJMc086492. No abstract available.

PMID:
19228632
[PubMed - indexed for MEDLINE]
Free Article
3.

FDA launches priority vouchers for neglected-disease drugs.

Waltz E.

Nat Biotechnol. 2008 Dec;26(12):1315-6. doi: 10.1038/nbt1208-1315. No abstract available.

PMID:
19060849
[PubMed - indexed for MEDLINE]
4.

Developing drugs for developing countries.

Ridley DB, Grabowski HG, Moe JL.

Health Aff (Millwood). 2006 Mar-Apr;25(2):313-24.

PMID:
16522573
[PubMed - indexed for MEDLINE]
Free Article
5.

FDA not NIH can speed new drugs.

Miller HI.

Nature. 2011 Apr 14;472(7342):169. doi: 10.1038/472169a. No abstract available.

PMID:
21490657
[PubMed - indexed for MEDLINE]
6.

A precarious balancing act--the role of the FDA as protector of public health and industry wealth.

McCabe AR.

Suffolk Univ Law Rev. 2003;36(3):787-819. No abstract available.

PMID:
16493844
[PubMed - indexed for MEDLINE]
7.

Orphanage at the FDA.

Chen E.

J Cardiovasc Transl Res. 2012 Oct;5(5):735-6. Epub 2010 Nov 16. No abstract available.

PMID:
21080134
[PubMed - indexed for MEDLINE]
8.

Drug safety reform at the FDA--pendulum swing or systematic improvement?

McClellan M.

N Engl J Med. 2007 Apr 26;356(17):1700-2. Epub 2007 Apr 13. No abstract available.

PMID:
17435081
[PubMed - indexed for MEDLINE]
Free Article
9.

Regulatory watch: FDA guidance on co-developing investigational drugs.

[No authors listed]

Nat Rev Drug Discov. 2011 Feb;10(2):86. doi: 10.1038/nrd3363. No abstract available.

PMID:
21283094
[PubMed - indexed for MEDLINE]
10.

Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decade.

Stefanakis R, Robertson AS, Ponder EL, Moree M.

PLoS Negl Trop Dis. 2012;6(10):e1803. doi: 10.1371/journal.pntd.0001803. Epub 2012 Oct 25. Review. No abstract available.

PMID:
23145186
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Bush tails follow-ons.

Fox J.

Nat Biotechnol. 2008 Apr;26(4):366. doi: 10.1038/nbt0408-366a. No abstract available.

PMID:
18392007
[PubMed - indexed for MEDLINE]
12.

The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries.

Shani S, Yahalom Z.

Food Drug Law J. 2008;63(3):701-11. No abstract available.

PMID:
19031669
[PubMed - indexed for MEDLINE]
13.

Drug and vaccine development for infectious diseases: the value of priority review vouchers.

Matheny J, Smith B, Courtney B, Mair M.

Clin Pharmacol Ther. 2009 Jun;85(6):571-2. doi: 10.1038/clpt.2009.53. No abstract available.

PMID:
19451907
[PubMed - indexed for MEDLINE]
14.

"Creating hope" and other incentives for drug development for children.

Connor E, Cure P.

Sci Transl Med. 2011 Jan 19;3(66):66cm1. doi: 10.1126/scitranslmed.3001707.

PMID:
21248312
[PubMed - indexed for MEDLINE]
15.

Balancing government regulation against access to drugs: address to Seton Hall University School of Law, February 16, 2007.

Meron D.

Seton Hall Law Rev. 2007;37(4):929-39. No abstract available.

PMID:
18363219
[PubMed - indexed for MEDLINE]
16.

Challenges and opportunities in bringing new medications to market for pediatric patients.

Upadhyaya HP, Gault L, Allen AJ.

J Am Acad Child Adolesc Psychiatry. 2009 Nov;48(11):1056-9. doi: 10.1097/CHI.0b013e3181baec67. No abstract available.

PMID:
19855220
[PubMed - indexed for MEDLINE]
17.

Development of novel combination therapies.

Woodcock J, Griffin JP, Behrman RE.

N Engl J Med. 2011 Mar 17;364(11):985-7. doi: 10.1056/NEJMp1101548. Epub 2011 Feb 16. No abstract available.

PMID:
21323535
[PubMed - indexed for MEDLINE]
Free Article
18.

FDA to steer nanotech.

Fox JL.

Nat Biotechnol. 2008 Oct;26(10):1060. doi: 10.1038/nbt1008-1060a. No abstract available.

PMID:
18846060
[PubMed - indexed for MEDLINE]
19.

Drug review "behind the curtain": a response to Professor Struve.

O'Reilly JT.

Cornell Law Rev. 2008 Jul;93(5):1075-90. No abstract available.

PMID:
18618971
[PubMed - indexed for MEDLINE]
20.

Raising the bar for market authorisation of new drugs.

Naci H, Cylus J, Vandoros S, Sato A, Perampaladas K.

BMJ. 2012 Aug 7;345:e4261. doi: 10.1136/bmj.e4261. No abstract available.

PMID:
22872693
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk